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The diagnosis of an inherited retinal dystrophy can have a significant
impact on both the physical and emotional lives of patients and their
families. In order to optimize the health and quality of life for these
individuals, a comprehensive approach to clinical care starting at the time
of diagnosis and continuing throughout their lifespan is critical. A
multidisciplinary team approach integrating ophthalmic and genetic
counseling services can optimize the diagnostic process and long-term
management of these patients. When vision loss is first appreciated, the
diagnostic specificity of an ophthalmic evaluation can be enhanced by a
detailed genetic work-up. This evaluation can help confirm the diagnosis
and allow for accurate risk counseling of the patient and their family.
Genetic counseling is critical at the time of diagnosis and is an opportunity
to provide education about the diagnosis, discuss low-vision rehabilitation,
and explore impacts on academics and employment. In addition,
counseling can help patients deal with the current psychological aspects of
their vision loss, prepare for the lifelong impact of their diagnosis and
over time adjust to the impact of progressive vision loss.
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Providing comprehensive genetic-focused clinical care
has always been essential for patients seen in pediatric
genetics, adult genetics, prenatal, and hereditary can-
cer clinics. The expanded ability to make genetic-based
diagnoses in a wider array of disciplines has resulted
in the expansion of genetic-focused clinical care into
multiple additional specialty areas including cardiology,
neurology, and the focus of this article: ophthalmology.
One of the largest categories of inherited eye disease
seen in ophthalmology is the inherited retinal dystro-
phies (IRDs). This group of conditions can have a
congenital to adult-onset and cause slowly progressive
vision loss, which can result in legal blindness. The
IRDs most commonly include diseases such as retinitis
pigmentosa (RP), Stargardt disease, cone dystrophies,
Leber congenital amauorsis, etc. Although collectively
this group of conditions is considered somewhat rare,
some conditions such as RP have a disease incidence
as high as 1/3500–1/5000 (1, 2).
While a great deal of progress has been made in
understanding the molecular basis of inherited eye
diseases, there appears to be a gap in the provision of
appropriate standardized specialized genetic ophthalmic
care (3, 4). Making the diagnosis is but one step in
providing comprehensive medical care for this group of
patients. Collaboration between the patient, their family,
the ophthalmologist, and the genetics expert can ensure
that appropriate clinical care is provided and that it is
personalized to the needs of the patient and their family.
Once a diagnosis is made, the patient should be made
aware of patient-friendly information about the disease,
its impact on societal functioning, supportive resources,
and reliable sources of information about the disease
(5). Combined with this education is the need to provide
support for the emotional impact of the actual diagnosis.
One of the key issues in thinking about an IRD is
the recognition that the disease is dynamic. Adjustment
will occur at multiple points in time and will require
183
Branham and Yashar
life-long education and support that explores both the
current state of the disease and helps the patient and
their family prepare for future stages of vision loss.
The diagnostic odyssey
Making a genetic diagnosis in a patient affected with an
inherited eye disease can be a complex process. While
the ability to validate the type and extent of vision
loss can be relatively straightforward, identifying the
underlying cause (i.e. the pathophysiology) of the IRD
is dependent on clinical diagnostic tools and expertise
that are available in a small subset of ophthalmology
practices. In an IRD clinic a patient’s presenting symp-
toms may be quite broad and relatively non-specific,
such as a decrease in visual acuity or nightblindness.
The ophthalmic diagnostic process refines these vague
symptoms to a more precise clinical diagnosis through
a complex series of diagnostic evaluations and clinical
examinations (Fig. 1). Subjective diagnostic evaluations
such as visual field, color vision testing, and visual
acuity measurements are combined with objective
ophthalmic testing, such as, electrophysiology, visually
evoked potential, fundus autofluorescense, angiogra-
phy, and optical coherence tomography. Patients may
have multiple evaluations by varied specialists before
a single unifying diagnosis is obtained. It has been
suggested that appropriate care requires a multidisci-
plinary approach comprised of integrated ophthalmic
and genetic diagnostic services that can provide high
quality ocular electrophysiology services, genetic test-
ing and interpretation, genetic counseling and effective
follow-up for both the patient and their at-risk family
members (5). This team-based approach is critical to
ensuring the visit is a success in terms of both the
diagnostic evaluation and patient satisfaction (6).
Family history is also a critical diagnostic tool of
the IRD clinical evaluation. A targeted family history
can elicit information on other family members with
a history of similar vision loss. It is essential to gather
information not only on the disease in other family
members but also on the age of disease onset. Asking
about the age of onset may be helpful in discerning
those truly affected by an IRD from those who had
vision loss due to common age-related conditions
such as cataracts or age-related macular degeneration.
In some families sharing information about vision
loss may be uncommon and uncomfortable, therefore,
asking questions about the ability of that person to
function in society (drive a car, read, etc) may also be
useful is discerning who else in the family is affected
(7). Combining the results of the diagnostic evaluations
with the results of the clinical examination and a
detailed pedigree can add specificity to the differential
diagnosis. The tentative clinical diagnosis can then be
refined through genetic testing.
When a patient and their family have had limited
experiences with ophthalmology it may be a difficult
and daunting task to navigate the process of getting
diagnosed with an IRD. It is initially challenging
to appreciate the distinctions between the various
categories of eye specialist, such as, an optometrist
vs an ophthalmologist. In addition, the limited avail-
ability of specialists with appropriate experiences with
inherited ophthalmic conditions, means that for many
individuals and their families the self-identification of
visual impairment or vision loss may be followed by
multiple evaluations by varied vision specialists before
a definitive diagnosis is made (3, 8). The uncertainty
that accompanies this process can leave patients both
frustrated and frightened as their vision slowly declines
and they have access to limited information on their
future. For some patients the end of the diagnostic
odyssey gives way to the larger difficulty of living with
a rare diagnosis about which their physician may have
limited experience in providing appropriate patient
support (8). These experiences highlight the need for
compassionate care at the time of diagnosis when
patients may have struggled with their vision loss for
a long period of time and their future is uncertain.
Genetic counseling
Genetic counseling can be integrated into ophthalmic
care for patients with diagnoses of IRDs using
several different service delivery models (9). In
some clinics, genetic counseling may be provided by
Fig. 1. The diagnostic process for inherited retinal dystrophies.
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ophthalmologists who are board certified in both oph-
thalmology and genetics or have fellowship training in
ophthalmic genetics. In other clinics, genetic counselors
may function as a permanent member of a multidisci-
plinary team working directly with an ophthalmologist
who specializes in IRDs. In academic centers, if the
ophthalmologist is not trained in genetics or does not
have a genetic counselor on staff, they may refer their
patients to mainstream genetics clinics (i.e. pediatric,
prenatal, or adult genetics) for this service. The
referring ophthalmologist may prefer that selected or
all aspects of genetic clinical care occur in the genetics
clinic (9). Genetic counselors are also available through
commercial companies to perform telephonic counsel-
ing for patients. When care is provided via telemedicine
it overcomes geographic boundaries for people who are
unable to travel to a clinic specializing in ophthalmic
genetic diseases or providing genetic counseling
services. Genetic counselors are trained to work with
patients with all forms of inherited diseases, including
inherited eye disease. However, these are a limited
number of genetic counselors who have expertise in
inherited eye diseases. Currently there are more than
30 genetic counselors with this expertise in the United
States and Canada (K. Branham, personal communica-
tion). They are employed at university hospitals, genetic
testing labs, government organizations, or businesses
that provide genetic counseling via telemedicine.
Genetic counseling for patients who are blind or
affected with vision loss poses unique challenges.
Genetic counselors often use visual aides to explain
complex medical and genetic information to their
patients. These aides have been shown to improve
patient recall and information retention from a coun-
seling session (10), however, they are challenging to
use during an ophthalmology session in which the
patient is dilated for their examination and also has
low vision. Genetic counselors who normally rely on
hand motions to aide in discussing complex genetic
issues with their patients, may find this is ineffective
when patients have difficulty seeing. Learning to use
only their spoken voice to work with patients may be
challenging. Similarly, the types of written documents
provided to patients with low vision may need to be
modified to accommodate various forms of vision
loss. When communicating with patients in written
text, large fonts may be helpful for patients who have
central vision loss (Stargardt disease, Best disease, etc),
but would not be as useful for patients with limited
visual fields (choroideremia, retinitis pigmentosa, etc).
Black text on white paper is generally easier to read
for a patient with low vision. Electronic formats such
as PDF may be useful for patients to use with certain
computer aided readers. Written summaries of clinical
discussions may only be useful if patients have access
to low-vision devices in their homes.
Genetic testing in inherited retinal disease
The recent rapid growth of genetic testing companies
has improved access to both this technology and the
accompanying diagnostic knowledge for both patients
and clinicians in all medical specialties, including
genetics and ophthalmology. Genetic testing is increas-
ingly being seen as a critical diagnostic tool in the field
of IRDs, it can be used to clarify the pattern of inher-
itance (and thus improve genetic counseling accuracy),
clarify the diagnosis (and sometimes provide prognostic
information), and optimize clinical care. Genetic coun-
selors’ specialized training makes them ideal members
of the ophthalmic health care team who can ensure that
prior to ordering genetic testing patients have the oppor-
tunity to discuss and evaluate the risks, benefits, and
limitations of the genetic testing and can serve as a
knowledgeable resource to explore the meaning of the
often complicated results.
In many IRDs, there is a great deal of genetic com-
plexity. RP is an example of an IRD which displays
extreme genetic heterogeneity with autosomal domi-
nant, autosomal recessive, X-linked, and less commonly
mitochondrial and digenic forms of disease. More than
56 genes have been identified as causative for non-
syndromic forms of RP (https://sph.uth.edu/Retnet/). In
some cases, careful pedigree analysis may not provide
definite answers regarding the pattern of inheritance
of disease in the family (11–14). Genetic testing in
IRDs may also be complicated by clinical heterogene-
ity. There are multiple examples where mutations in a
single gene result in clinically distinct form of an IRD.
For example, mutations in the RDS/peripherin gene
(PRPH2 ) can cause RP and several clinically distinct
types of macular dystrophy (15–17).
While in most cases, genetic testing can be used to
add specificity to the diagnosis of the well-phenotyped
patient, in other cases, genetic testing may help pro-
vide a diagnosis for a patient in which repeated diag-
nostic ophthalmic evaluations have failed to identify
the underlying disease. For example, Leber congeni-
tal amaurosis, achromatopsia, and congenital stationary
night blindness have quite different longitudinal out-
comes for patients, yet in an infant or young child,
the overlapping clinical symptoms include decreased
visual acuity and nystagmus (18). Genetic testing of
an infant/young child presenting with these symptoms,
may identify the diagnosis and provide prognostic infor-
mation to both parents and patients.
Genetic testing can also optimize clinical care
by allowing patients to take advantage of emerging
targeted therapeutics. In some diseases, identifying the
genetic basis for disease allows a patient to prepare
for current and future clinical trials. Currently clinical
trials are available for patients who have vision loss
due to mutations in RPE65 (19–21), LRAT , MYO7A
(22), ABCA4 , and CHM (www.clinicaltrials.gov).
Future trials currently under laboratory investigation
for several other diseases include IRDs caused by
mutations in RPGR (23), RS1 (24–26), CNGA3 (27),
and CNGB3 (28, 29). Moreover, there is evidence that
certain environmental factors may be more harmful
in specific genetic contexts. Animal studies in ABCA4
−/− mice showed increased lipofuscin deposits,
suggesting that patients affected with Stargardt disease
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should avoid vitamin A supplementation (30). Patients
with RHO mutations are also particularly sensitive to
phototoxic effects (31) and should be advised to avoid
excess sun exposure.
Identifying the genetic basis for the patient’s IRD,
not only has implications for the patient, but impacts
the entire family overall. Genetic information may be
useful for other family members who wish to under-
stand their own risk to develop the disease and/or their
own risk for having children affected with an IRD. As
an example, a patient presented to our clinic at age 73
having been diagnosed in childhood with a slowly pro-
gressive macular degeneration. Upon gathering family
history information, we learned that his brother was
similarly affected and he had a grandson, through his
daughter, who suffered a retinal detachment in infancy.
No unifying diagnosis had been made in this family.
Although our patient’s fundus findings had degenerated
to the point where making a specific diagnosis was
challenging, based on the clinical and family history we
suspected a diagnosis of X-linked retinoshisis (XLRS).
This condition is characterized by juvenile onset
macular degeneration and splitting of the retinal layers
(32). XLRS genetic testing was performed through
the eyeGENE® study at the National Eye Institute
(http://www.nei.nih.gov/resources/eyegene.asp) and
identified a mutation in the RS1 gene. Following the
identification of a disease-causing mutation in our
patient, other at-risk members of his family were able
to have genetic testing that helped clarify their risk
of developing this condition or being carriers. In this
case, defining the genetic basis of the IRD helped us to
not only clarify the diagnosis for our patient, but also
helped individual family members define their specific
disease risk. In addition, this knowledge was useful in
future family planning.
Over the last 20 years, there has been a shift in
the number and availability of clinical tests available
for IRDs. Initially, only research labs performed
genetic testing for these patients. While many of
these research labs still exist, there are currently
more than 12 commercial testing labs in the United
States that offer genetic testing for ophthalmic eye
diseases (http://www.ncbi.nlm.nih.gov/gtr/), including
three labs which specialize exclusively in testing for
ophthalmic disease. Numerous approaches can be used
when ordering IRD testing, including targeted testing
for specific mutations, panel-based testing of multiple
clinically related genes, and the broadest approaches
yet of whole exome/genome sequencing. Financially,
it makes sense to take the most targeted testing
approach available on a well-phenotyped individual
(as described above) – the phenotype and inheritance
pattern guide the test choice. This approach is supported
by the American Academy of Ophthalmology Taskforce
on Genetic Testing (33). However, for many IRD
diagnoses, the extensive locus and allelic heterogeneity
can make targeted testing challenging.
Despite the availability and usefulness of genetic
testing, the question remains: Should genetic testing
be the standard of care for IRD? The American
Academy of Ophthalmology Task Force on Genetic
Testing recommends that genetic testing be offered to
all patients with clinical findings of a Mendelian genetic
disease, for which, genetic testing is available (33). It is
imperative, however, that the technology is integrated
into the clinic appropriately. As a clinical tool this
technology is a powerful adjunct to clinical diagnosis,
however, appropriate utilization requires not only a
comprehensive understanding of the pathophysiology of
the disease and the varied molecular mechanisms that
can result in a single clinical entity, but also careful
consideration of the implications of making a molecular
diagnosis for both the patient and the rest of their
family. In unaffected family members it is critical to
carefully consider the implications of making diagnosis
in a healthy individual, that is, predictive and/or
presympomatic testing before ordering the test. Patients
and their families should be aware of the medical and
psychosocial implications of a diagnosis and genetic
counselors can have an active role in this process.
Living with the diagnosis of an IRD throughout
the life span
Multidisciplinary team members who care for patients
affected with IRDs should be aware of the many
challenges which can affect this group of patients. As
potential members of these teams, genetic counselors
can provide a comprehensive perspective on an IRD
to an affected patient that helps them understand the
impacts of the diagnosis on both their current and future
health. Counseling in this context can include providing
short-term psychosocial support which helps the patient
adjust to the vision loss, identifying resources that
can improve their quality of life, and helping them to
appreciate the value of this type of assistance. Numer-
ous community, state, and national resources exist for
this patient population (Table 1). Their support can
augment that of the multidisciplinary health care team.
These government services, non-profit organizations,
and clinic-based services can provide patients with
long-term psychosocial support, low-vision rehabil-
itation, and vocational training or retraining. It is
critical that patients with an IRD develop a network of
resources that help them adjust to the both the physical
and psychological ramifications of their diagnosis.
Following the identification of an IRD, patients
should be aware that their visual impairment may
impact their education, employment, mobility, social-
ization, psychosocial development, utilization of assis-
tive technologies and mental health status (34, 35).
However, not all individuals with an IRD will need
the same accommodations or encounter the same chal-
lenges related to their vision. Due to variability in the
types (central vs peripheral) and rates of vision loss
(blindness as a child vs an adult), low vision, rehabilita-
tion, and educational needs must be targeted to the spe-
cific needs of an individual and adjusted over time (36).
It is critical to recognize that a diagnosis of vision
loss also results in varying degrees of stress and
the emotional consequences must be acknowledged,
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Table 1. Support resources for patients with inherited retinal dystrophies
Level of resource Type Local examples Roles
Community based resources Non-profit organization Support groups Psychosocial support, patient
education
Clinical Low Vision Clinic Low vision sides, life skills
training
State based resources Government Bureau of Services for Blind Person
(Michigan)
Vocational training, advocacy
Non-profit organization Michigan Parents of Visually
Impaired
Support, advocacy
National resources Government National Eye Institute Research, education
Government eyeGENE Research
Non-profit organization National Federation for the Blind Advocacy, education, research
Foundation Foundation Fighting Blindness Fundraising for research,
education, advocacy
Non-profit organization National Organization for Albinism
and Hypopigmentation (NOAH)
Support, education, advocacy
accepted and accommodated. Both quantitative and
qualitative studies have found that patients need time to
react to the trauma of the diagnosis itself. A diagnosis
of vision loss often negatively impacts psychosocial
and social well-being, and patients need assistance
coping with their diagnosis (37). In individuals with a
diagnosis of RP it has been reported that the increasing
threat of vision loss and the resulting loss of mobility
and independence are sources of considerable stress
(38–40). The level of emotional trauma is higher than
that experienced by individuals who are adjusting to
a more common diagnosis such as diabetes. For those
with vision loss, this trauma appears to be reinforced
by a lack of information about the diagnosis that
is leading to their vision loss, limited support from
health care providers, and fear of increasing physical
dependence on others (friends and family) who may
not fully understand the diagnosis and the continuous
need to adapt and adjust to progressive vision loss
(41). The ability to use assistive technology and the
hope that research will help find a cure are critical to
the process of actively fighting the disease. Overall,
there often appears to be a high degree of resiliency
that is grounded in the perspective that there are
other diagnoses or life situations that could be worse.
Individuals with RP have been found to use a variety of
coping strategies to manage the stress associated with
vision loss. These include humor, social support and
communication from others with a similar diagnosis and
the ability to learn to ‘let it go’ (38).
When hereditary vision loss is diagnosed in children,
it is critical to consider the impact both on the child with
the vision loss and their family members. For children
who have experienced a period of normal vision, the
issues are quite similar to those that are experienced
by adults with vision loss and include implementing
accommodations in educational settings, independence
as related to driving and the ability to live outside
the family home, disclosure of vision loss to friends, life
partners and coworkers and identification of appropriate
employment (42). The issues are also similar for
children with congenital vision loss. For both groups
of children with vision loss there are also challenges
in social domains. Studies of Canadian youth who are
blind or visually impaired have suggested that it may
be particularly difficult for visually impaired children
as they compare themselves directly to sighted peers
and they struggle with disclosure of their impairment
to their peers (42). When hereditary vision loss is
considered as a chronic health problem, the impact
on parents and family can include guilt over the
inherited nature of the diagnosis, fear of recurrence
and concerns about caring for children with vision loss
(4, 41, 42). Studies of the health related quality of
life (HRQoL) and psychosocial impact of an IRD on
children and their families found that affected children
in the study had lower HRQoL scores than other
children with chronic systemic disorders (42). They also
found that that their self-assessed quality of life did not
correlate with objective measures of visual acuity and
that in general parents assessed their child’s HRQoL
as lower than that reported by the child themselves.
This pessimism mirrors that seen in other studies of
parents of children with disabilities and highlights the
importance of actively engaging parents so that they do
not lower their expectations of their child’s engagement
in daily living activities. In addition it is important to
acknowledge the stress of having a child with a chronic
disability and identify ways of alleviating this burden.
In total the studies to date highlight the importance
of working with all patients with inherited progressive
retinal disease to acknowledge current and future
vision loss and to accept their disease but limit the
attempts to aggressively define when a patient will go
blind. It can be very helpful to reassure patients and
their families when possible that a diagnosis of an IRD
does not mean that they will necessarily go completely
blind (43). Concomitantly it is critical to be honest
with patients about activities that will need to be
altered or curtailed and help them identify resources to
help deal with these changes, that is, the potential need
for accommodations at school and/or work and the
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utility of assistive devices and low-vision rehabilitation
to help with reading and mobility. The progressive
nature of vision loss requires that regular follow-up
and counseling is provided. This support is particularly
important in light of the varied sources of stress, both
physical and emotional, that a diagnosis can evoke.
Using approaches grounded in decision-making can be
helpful in working with patients as they endeavor to
accept their diagnosis and alter their lives to accom-
modate their vision loss (44, 45). The study on patient
adjustment to progressive vision loss by Hayeems
et al. (46) highlights a number of practical steps that
can help patients adjust to their diagnosis including
(i) work with the patient to understand why they believe
they have their disability and normalize their search
for meaning; (ii) let the patient know that the diagnosis
has changed their identity and that it may be difficult
to share this information; (iii) normalize the patient’s
reaction and help them to understand similar reactions
in others with the diagnosis; (iv) help the patient think
about possible lifestyle changes and identify and weigh
the risk and benefits of these lifestyle changes; (v) help
the patient to tailor their decision to their current vision
and their psychological readiness; (vi) provide positive
support by acknowledging the patient’s progress in
discussing these issues and (vii) anticipate future issues
by providing guidance and supportive resources.
Conclusions
A diagnosis of an IRD has significant physical and emo-
tional impacts that occur both at the time of diagnosis
and regularly through a patient’s life as their vision
degenerates. Making a diagnosis that is within this cate-
gory of conditions, can be challenging, and patients will
benefit from the input of multiple health care providers,
including ophthalmologists, genetic counselors, and
support staff. Taking a multidisciplinary team approach
to the diagnostic process, the genetic testing process,
and throughout the lifelong management of the diagno-
sis is critical to ensure that patients have the necessary
level of support. Managing the diagnosis of an IRD
requires assistance that considers both the physical and
emotional dimensions of vision loss. In addition, the
fact that the vision loss is inherited means that the diag-
nosis directly affects both the patient and their family.
The ways in which genetics is integrated into ophthal-
mology is a useful paradigm for understanding how it
might be integrated into other medical specialties.
With the rapid development of new genetic technolo-
gies (such as exome and whole genome sequencing)
and swift integration into clinic care, it is increasingly
challenging to determine the optimal ways of utilizing
molecular diagnostics to serve our patients. Concomi-
tant with these new advances is the responsibility to
ensure that the translation from research discovery to
clinical tool is appropriately integrated. As we continue
to learn more about the genetic basis for inherited reti-
nal diseases it will be critically important to ensure that
a multidisciplinary team composed of physicians and
genetic counselors is a standard of care for all patients.
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